| Similar Articles |
|---|
 |
The Motley Fool
October 21, 2010
Brian Orelli |
Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.   |
The Motley Fool
April 19, 2011
Brian Orelli |
See You on the Other Side of the Cliff Lilly beats, but there's still a lot of unknowns. Can the company continue the trend through the patent cliff? |
The Motley Fool
July 23, 2010
Brian Orelli |
Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future? |
The Motley Fool
July 21, 2005
Stephen D. Simpson |
Tiger Lilly or Wilting Daisy? For now, Lilly seems to me to be a middle-of-the-road type of pharmaceutical stock. There are plenty of worse ideas out there, but there are better ideas, as well. |
The Motley Fool
April 22, 2008
Brian Lawler |
Lilly in Full Financial Bloom Pharmaceutical Eli Lilly boosts revenue in the first quarter, but its drug-pipeline progress falls short of spectacular. |
The Motley Fool
October 20, 2006
Brian Lawler |
Lilly Pads Its Earnings Lilly reports third-quarter 2006 numbers and gobbles up Cialis. Investors, take note. |
The Motley Fool
October 22, 2007
Brian Lawler |
Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future. |
The Motley Fool
July 23, 2009
Brian Orelli |
The Slowly Wilting Lilly Nothing can save this drug company. |
The Motley Fool
January 26, 2006
Stephen D. Simpson |
Will New Drugs Gild Lilly? Although Lilly's late-stage pipeline is weak, newer drugs should still be able to grow. Investors, this is still a mediocre investment option. |
The Motley Fool
June 25, 2008
Brian Lawler |
Why the Lilly Delay, FDA? A government review of the company's top drug candidate gets pushed back. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
Lilly's No Wallflower The drugmaker posts tepid results as it bides time before new products hit the market. Lilly's valuation suggests that Wall Street has faith that those new drugs will come through. |
The Motley Fool
April 22, 2011
Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. |
The Motley Fool
January 28, 2011
Brian Orelli |
Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison. |
The Motley Fool
December 10, 2009
Brian Orelli |
A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own. |
The Motley Fool
April 20, 2009
Brian Orelli |
A Cheer and a Boo for Eli Lilly Cost-cutting is nice, but it doesn't slow down the drive toward the patent cliff. Lilly needs to be on the lookout for other partnerships to fill in the upcoming revenue holes. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
January 5, 2004
Alyce Lomax |
Side Effects at Lilly? Growing profits, with earnings pains. |
The Motley Fool
March 23, 2011
Brian Orelli |
Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own. |
The Motley Fool
April 15, 2005
Brian Gorman |
Relief Pitch for Eli Lilly A ruling upholding the Zyprexa patent is good news for Lilly, but promising drugs in the pipeline are even more encouraging. Investors, take note. |
The Motley Fool
October 20, 2005
Stephen D. Simpson |
Lilly Steady As She Goes In-line performance is probably the best that investors in this pharmaceutical could have hoped for this quarter. |
The Motley Fool
December 12, 2008
Brian Orelli |
A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors. |
The Motley Fool
July 21, 2006
Stephen D. Simpson |
Lilly Wilts Neither the valuation nor the pipeline of this pharma makes for a compelling investment case. |
The Motley Fool
October 24, 2008
Brian Orelli |
Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes. |
The Motley Fool
August 13, 2010
Brian Orelli |
Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like. |
BusinessWeek
March 20, 2006
Gene G. Marcial |
Lilly Is Starting To Bloom Big pharma has been in the doldrums for years, ravaged by generic rivals, class actions, and trickling product pipelines. But some pockets are perking up. |
The Motley Fool
December 29, 2006
Brian Lawler |
Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note. |
The Motley Fool
May 31, 2007
Brian Lawler |
Dueling Fools: Eli Lilly Bear Rebuttal Shareholders who buy into Lilly at its current valuation just won't have the same opportunity for stock price appreciation as those who bought shares in the late '80s or early '90s. |
The Motley Fool
October 19, 2006
Brian Lawler |
Amylin's One-Drug Wonder Unfortunately, with research and development costs growing to $54 million from $33 million last year, Amylin is still a few quarters away from profitability. Diabetes drug Byetta is set to boost Amylin's sales. Investors, take note. |
The Motley Fool
January 31, 2007
Brian Lawler |
Lilly Floats Atop Rivals The large-cap pharma posts slow, steady growth. Investors, take note. |
The Motley Fool
March 20, 2008
Brian Lawler |
The AIR's Knocked Out of Alkermes Drug developer Alkermes initiates a round of cost-cutting. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Most Interesting FDA Review for 2008 Eli Lilly preps for an upcoming FDA review of its top pipeline drug, the blood thinner prasugrel. |
The Motley Fool
July 26, 2007
Brian Lawler |
Lilly Doesn't Wilt The second quarter was another good one for Eli Lilly. Top-line and bottom-line both grew. |
The Motley Fool
October 18, 2007
Brian Orelli |
Amylin: Waiting on the Future Research and development costs drag down the drug developer's bottom line. Investors, take note. |
The Motley Fool
May 31, 2007
Ryan Fuhrmann |
Dueling Fools: Eli Lilly Bull Thanks to a couple of recent developments and a focus on research & development, the pharma giant is a worthy contender for health-care exposure in investors' portfolios. |
The Motley Fool
June 16, 2010
Brian Orelli |
A Drop on Bad News, but It Was a Long Shot Anyway Bydureon, Amylin Pharmaceuticals and Eli Lilly's once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials but it will have a tough time going after the monotherapy market. |
The Motley Fool
November 5, 2010
Brian Orelli |
Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
May 24, 2011
Brian Orelli |
If at First You Don't Succeed, Spin It Off Eli Lilly ditches Xigris by spinning off BioCritica. |
The Motley Fool
October 7, 2008
Brian Orelli |
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. |
The Motley Fool
May 16, 2011
Brian Orelli |
Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly. |
The Motley Fool
October 31, 2007
Brian Lawler |
Nastech Still Breathing Coming phase 2 results on four different compounds will help investors assess how well Nastech's nasally-administered drugs might sell. Investors, take note. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
June 18, 2010
Brian Orelli |
Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed. |
The Motley Fool
October 20, 2010
Brian Orelli |
There Are No Safe Biotech Investments Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Administration had asked for more data before approving its once-weekly diabetes drug Bydureon. |
The Motley Fool
January 27, 2011
Brian Orelli |
Amylin Timeline Shortened -- Maybe Revenue down 6% year over year. Prescriptions of the company's top-selling drug, Byetta, down 5.9% quarter over quarter. Amylin Pharmaceuticals' fourth quarter wasn't pretty. |
The Motley Fool
November 9, 2011
Brian Orelli |
Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
October 18, 2010
Brian Orelli |
Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs. |
